Fennec Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Record sales and financial strength marked 2025, with major growth in PEDMARK and expansion into new markets. All shareholder proposals passed, including board elections and equity plan amendments. Strategic initiatives target broader clinical adoption and global reach.
-
PEDMARK, the only approved agent to prevent cisplatin-induced hearing loss, is expanding from pediatrics into the larger AYA market, driving record revenues and broader adoption. Ongoing real-world studies and global partnerships aim to unlock further growth and long-term exclusivity.
-
Q1 2026 saw 73% year-over-year sales growth, driven by commercial expansion and strong demand in key cancer segments. Operational improvements led to record infusions and high conversion rates, while new clinical studies and international launches are set to support further growth.
Fiscal Year 2025
-
Record 2025 sales and robust AYA growth drove a 50% revenue increase, supported by expanded teams, new clinical evidence, and a strengthened balance sheet. U.S. exclusivity for PEDMARK is secured through 2033, with major European launches and further growth expected in 2026.
-
Pedmark is the only FDA-approved therapy for preventing Cisplatin-induced hearing loss in pediatric and AYA patients, with expanding use supported by strong clinical data and recent Japanese trial results. Commercial growth is driven by increased awareness, expanded infrastructure, and successful payer access, with ongoing global launches and robust IP protection.
-
PEDMARK achieved record sales and three consecutive quarters of growth, driven by expanded leadership, new global partnerships, and broadened market access, especially in the AYA segment. Strong IP, reimbursement success, and robust patient support position the company for continued momentum.
-
Q2 2025 net product sales grew 33% year-over-year to $9.7M, marking the third consecutive quarter of sequential growth. PEDMARK adoption expanded with 14 new accounts, and EU commercialization via Norgine is gaining traction. Cash OpEx is expected to decrease in H2 2025.
-
PEDMARK’s unique FDA-approved position in preventing cisplatin-induced hearing loss is driving growth, with recent expansion into the AYA segment and strong international partnerships. Financials are approaching break-even, and further milestones in Europe and Japan are expected to accelerate value.
-
Q1 2025 saw strong sales growth, improved operational execution, and expanded PEDMARK adoption in both U.S. and international markets. Enhanced targeting and patient support drove adherence, while cash burn and OpEx remained controlled. International launches and clinical milestones are expected to further boost growth in 2025.
Fiscal Year 2024
-
Revenue grew 40% year-over-year to $29.6M in 2024, driven by expanding PEDMARK adoption in both pediatric and AYA oncology segments. European launches and strong cash position support further growth, with significant sales acceleration expected in the second half of 2025.
-
Q3 2024 saw net product sales rise to $7.0M, with strong AYA segment growth and >90% reimbursement. International launches and a robust cash position support a positive outlook, while new leadership and academic endorsements drive further adoption.
-
Fennec Pharmaceuticals highlighted Pedmark's unique position as the only FDA and EMA-approved treatment for cisplatin-induced hearing loss in children, with strong clinical results and expanding commercial reach through a major licensing deal. Financials show a solid cash position and a clear path to profitability.
-
Q2 2024 saw PEDMARK net sales rise 120% year-over-year to $7.3M, driven by expanded NCCN guidelines and new AYA market access. The Norgine partnership provides significant upfront and milestone payments, supporting a strong cash position and global expansion plans.